1-3 of 3
David R. Spigel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

Tina Cascone, Gozde Kar, Jonathan D. Spicer, Rosario García-Campelo, Walter Weder, Davey B. Daniel, David R. Spigel, Maen Hussein, Julien Mazieres, Julio Oliveira, Edwin H. Yau, Alexander I. Spira, Valsamo Anagnostou, Raymond Mager, Oday Hamid, Lin-Yang Cheng, Ying Zheng, Jorge Blando, Tze Heng Tan, Michael Surace, Jaime Rodriguez-Canales, Vancheswaran Gopalakrishnan, Bret R. Sellman, Italia Grenga, Yee Soo-Hoo, Rakesh Kumar, Lara McGrath, Patrick M. Forde
Journal: Cancer Discovery
Cancer Discov (2023) 13 (11): 2394–2411.
https://doi.org/10.1158/2159-8290.CD-23-0436
Published: 01 November 2023
View article titled, Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Open the PDF for Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial in another window
Includes: Supplementary data
Journal Articles

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

Claire F. Friedman, John D. Hainsworth, Razelle Kurzrock, David R. Spigel, Howard A. Burris, III, Christopher J. Sweeney, Funda Meric-Bernstam, Yong Wang, Jonathan Levy, Jessica Grindheim, David S. Shames, Katja Schulze, Arisha Patel, Charles Swanton
Journal: Cancer Discovery
Cancer Discov (2022) 12 (3): 654–669.
https://doi.org/10.1158/2159-8290.CD-21-0450
Published: 01 March 2022
View article titled, Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
Open the PDF for Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study in another window
Includes: Supplementary data
Journal Articles

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle M. Greenawalt, Matthew D. Hellmann, Mark M. Awad, Justin F. Gainor, Alexa B. Schrock, Ryan J. Hartmaier, Sally E. Trabucco, Laurie Gay, Siraj M. Ali, Julia A. Elvin, Gaurav Singal, Jeffrey S. Ross, David Fabrizio, Peter M. Szabo, Han Chang, Ariella Sasson, Sujaya Srinivasan, Stefan Kirov, Joseph Szustakowski, Patrik Vitazka, Robin Edwards, Jose A. Bufill, Neelesh Sharma, Sai-Hong I. Ou, Nir Peled, David R. Spigel, Hira Rizvi, Elizabeth Jimenez Aguilar, Brett W. Carter, Jeremy Erasmus, Darragh F. Halpenny, Andrew J. Plodkowski, Niamh M. Long, Mizuki Nishino, Warren L. Denning, Ana Galan-Cobo, Haifa Hamdi, Taghreed Hirz, Pan Tong, Jing Wang, Jaime Rodriguez-Canales, Pamela A. Villalobos, Edwin R. Parra, Neda Kalhor, Lynette M. Sholl, Jennifer L. Sauter, Achim A. Jungbluth, Mari Mino-Kenudson, Roxana Azimi, Yasir Y. Elamin, Jianjun Zhang, Giulia C. Leonardi, Fei Jiang, Kwok-Kin Wong, J. Jack Lee, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, Vincent A. Miller, Garrett M. Frampton, Jedd D. Wolchok, Alice T. Shaw, Pasi A. Jänne, Philip J. Stephens, Charles M. Rudin, William J. Geese, Lee A. Albacker, John V. Heymach
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (7): 822–835.
https://doi.org/10.1158/2159-8290.CD-18-0099
Published: 01 July 2018
View article titled, <em>STK11/LKB1</em> Mutations and PD-1 Inhibitor Resistance in <em>KRAS</em>-Mutant Lung Adenocarcinoma
Open the PDF for <em>STK11/LKB1</em> Mutations and PD-1 Inhibitor Resistance in <em>KRAS</em>-Mutant Lung Adenocarcinoma in another window
Includes: Supplementary data